Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 4/20 | 0.68 |
| ▸ | GSR | P00390 | 1/20 | 0.49 |
| ▸ | RIMKLA | Q8IXN7 | 1/20 | 0.47 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.47 |
| ▸ | NOD1 | Q9Y239 | 2/20 | 0.45 |
| ▸ | GNPAT | O15228 | 2/20 | 0.44 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.44 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.44 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.44 |
| ▸ | CPB2 | Q96IY4 | 2/20 | 0.43 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.42 |
| ▸ | DPP4 | P27487 | 1/20 | 0.42 |
| ▸ | SLC15A2 | Q16348 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30859428 | 1.00 | FOLH1 (0.68) | FOLH1GSRRIMKLANAALAD2NOD1 | |
| SCHEMBL30099724 | 1.00 | FOLH1 (0.68) | FOLH1GSRRIMKLANAALAD2NOD1 | |
| SCHEMBL30099516 | 1.00 | FOLH1 (0.68) | FOLH1GSRRIMKLANAALAD2NOD1 | |
| SCHEMBL30099573 | 1.00 | FOLH1 (0.68) | FOLH1GSRRIMKLANAALAD2NOD1 | |
| SCHEMBL31635787 | 1.00 | FOLH1 (0.68) | FOLH1GSRRIMKLANAALAD2NOD1 | |
| SCHEMBL31635788 | 1.00 | FOLH1 (0.68) | FOLH1GSRRIMKLANAALAD2NOD1 | |
| SCHEMBL29373156 | 1.00 | FOLH1 (0.68) | FOLH1GSRRIMKLANAALAD2NOD1 | |
| SCHEMBL7166207 | 1.00 | FOLH1 (0.68) | FOLH1GSRRIMKLANAALAD2NOD1 | |
| SCHEMBL31635789 | 1.00 | FOLH1 (0.68) | FOLH1GSRRIMKLANAALAD2NOD1 | |
| SCHEMBL31635790 | 1.00 | FOLH1 (0.68) | FOLH1GSRRIMKLANAALAD2NOD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240173390-A1 | PEPTIDE VACCINE FORMULATIONS AND USE THEREOF FOR INDUCING AN IMMUNE RESPONSE | THE U.S.A, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2024-05-30 | — | — | US | disclosed |
| US-11938177-B2 | Peptide vaccine formulations and use thereof for inducing an immune response | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2024-03-26 | — | — | US | disclosed |
| US-20220152170-A1 | PEPTIDE VACCINE FORMULATIONS AND USE THEREOF FOR INDUCING AN IMMUNE RESPONSE | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVIC (US) | 2022-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240173390-A1 | PEPTIDE VACCINE FORMULATIONS AND USE THEREOF FOR INDUCING AN IMMUNE RESPONSE | NGLY1, MYD88, SPPL2B | FOLH1 1386/4885GSR 4497/4885RIMKLA 2200/4885 |
| US-11938177-B2 | Peptide vaccine formulations and use thereof for inducing an immune response | NGLY1, MYD88, SPPL2B | FOLH1 1386/4885GSR 4497/4885RIMKLA 2200/4885 |
| US-20220152170-A1 | PEPTIDE VACCINE FORMULATIONS AND USE THEREOF FOR INDUCING AN IMMUNE RESPONSE | NGLY1, MYD88, SPPL2B | FOLH1 1386/4885GSR 4497/4885RIMKLA 2200/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.